
GLP-1 Agonists in Serious Mental Illness: Current Evidence
In this episode, we explore whether GLP-1 agonists like semaglutide can tackle the metabolic toll of antipsychotics in schizophrenia. Can a drug famous for celebrity weight loss actually protect our most vulnerable psychiatric patients from diabetes and obesity before the damage is done? Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 84 GLP-1s in Schizophrenia: Should Semaglutide Be Added for Metabolic Management?
Publisher
Psychopharmacology and Psychiatry Updates
Link
psychopharmacology.libsyn.com/glp-1-agonists-in-serious-mental-illness-current-evidence
Published
August 29, 2026
Duration
15 min
Format
Podcast
Category
Lifestyle · Medicine
Source
RSS feed
Host
Psychopharmacology Institute
Psychopharmacology and Psychiatry Updates
@psychopharmacologyandpsychia
#agonists #seriousmentalillness #currentevidence #medicine
